Viral Hepatitis

Latest Articles

Short-Term Glecaprevir/Pibrentasvir Safe, Efficacious for Treatment-Naive HCV

By

Bradley van Paridon

Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.

HBV Screening Beneficial in Immunocompromised Pediatric Patients With Rheumatologic Conditions and IBD

By

Amit Akirov, MD

Researchers evaluated the prevalence of serologic immunity against hepatitis B virus in immunocompromised patients with pediatric-onset inflammatory bowel disease and rheumatologic diseases.

ASCO Issues Provisional Opinion Update on Hepatitis B Screening

By

Leah Lawrence

ASCO recommends that patients with newly diagnosed cancer slated to receive systemic anticancer meds be tested for HBV by 3 tests prior to starting therapy.

CDC Releases Guidelines for Occupational Exposure to HCV

By

Zahra Masoud

New CDC guidelines recommend a test-and-treat approach for healthcare personnel who may have been exposed to acute hepatitis C virus infection at work.

CDC Guidance Issued for Testing, Management of Healthcare Personnel Exposed to HCV

Recommendations are presented for testing and clinical management of health care personnel exposed to the hepatitis C virus in a US Centers for Disease Control and Prevention guidance report.

Routine Hepatitis C Testing at Federally Qualified Health Centers Would Be Cost-Effective

Routine hepatitis C virus testing at federally qualified health centers would be cost-effective and could improve outcomes for people with HCV infections.

Efficacy of Bundled HIV, HCV Testing Examined in Substance Abuse Disorders

By

Bradley van Paridon

By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.

Small Case Series Describes Clinical Course of Patients With COVID-19 and Chronic HBV

By

Brandon May

Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.

Tenofovir Disoproxil Fumarate Associated With Higher Rates of Elastographic Reversion in Patients With Hepatitis B

By

Jessica Nye, PhD

TDF therapy resulted in greater rates of elastographic reversion of cirrhosis in patients with chronic hepatitis B at year 5 compared with entecavir.

Combined Hepatitis A/Typhus Vaccine, Safe and Tolerable For Children

By

Bradley van Paridon

A combined hepatitis A and typhus vaccine in Australia for use in patients aged > 16 years was shown to be well-tolerated in children aged 2 to 16 years.

Besifovir Dipivoxil Maleate Effective, Safe for Long-Term Treatment of Hepatitis B

By

Emily Pond

Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).

Statin Use and Acute Liver Injury Among Veterans With and Without HCV, HIV

By

Bradley van Paridon

Patients using statins had a lower risk for any acute liver injury outcome within 18 months compared with non-users, regardless of HIV and/or hepatitis C virus (HCV) status.

USPSTF Recommends Hep B Screening for Those at Increased Risk

The U.S. Preventive Services Task Force recommends screening adolescents and adults at increased risk for hepatitis B virus infection.

Liver Forum Releases Guidelines for Assessing Patients with NASH

By

Jessica Nye, PhD

The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.

Serologic Markers for Diagnosing Hepatitis E Infection

By

Bradley van Paridon

The persistence of hepatitis E virus (HEV) markers after acute self-limited hepatitis E was assessed and according to the data published in Journal of Viral Hepatitis, the serologic test HEV-Ag performed best overall.

Infective Endocarditis Rates Markedly Increased in Young People With HCV, Opioid Use Disorder

By

Sweta Gupta

In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.

Universal Testing May Help Identify HCV in Pediatric Population

By

Zahra Masoud

New polices, including testing for hepatitis C virus (HCV) during pregnancy, may increase HCV identification in the pediatric population by addressing gaps in maternal HCV testing.

Bundled Rapid HIV/Hep C Testing May Improve Infection Awareness

For people with substance use disorders, combining HIV and hepatitis C virus (HCV) testing and providing immediate test results may increase the number of people who are aware of their infection status.

Hydromorphone Controlled-Release Dispensing Rates May Predict HCV Incidence

By

Zahra Masoud

Compared with all opioid prescriptions, a higher hydromorphone controlled-release dispensing rate was a strong predictor of hepatitis C virus incidence.

Epclusa Approved for Pediatric Patients with Chronic Hepatitis C Infection

By

Brian Park, PharmD

Epclusa is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.